Related Experiment Videos
Gene therapy of prostate cancer: p53, suicidal genes, and other targets
1Institute of Molecular Medical Sciences, Palo Alto, California 94306, USA.
Abstract:
Prostate tumor initiation and progression to malignancy may involve upregulation of the androgen receptor known to stimulate prostate cell proliferation; other etiologic mechanisms may include dysfunction of the apoptotic pathway but also deregulation in signal transduction and control of the cell cycle in prostate tissue; such abnormalities could arise from overexpression or mutations in a number of oncogenes or down-regulation by inactivating mutations, allelic loss, or other epigenetic mechanisms in tumor suppressor genes. The advantages and drawbacks of various delivery systems (retroviral, adenoviral, liposomes) used for human gene therapy are being considered. Several ex vivo and in vivo as well as cell culture studies are suggested for the therapy of the human prostate cancer using transfer and expression of genes that might be implicated in prostate carcinogenesis especially of the tumor suppressor p53. Expression of suicidal genes in prostate cancer cells using prostate-specific promoter and enhancer elements as well as targeting of the androgen receptor or the insulin-like growth factor genes with triplex technology in prostate cancer cells and their metastases, is expected to be of therapeutic value.
Insights
Gene therapy offers potential for prostate cancer treatment by targeting genes involved in tumor growth and cell cycle regulation. Research explores delivery systems and gene expression for therapeutic benefit in prostate cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Prostate cancer development involves androgen receptor signaling, apoptosis dysfunction, and cell cycle deregulation.
- Aberrant gene expression, including oncogenes and tumor suppressor genes, contributes to prostate carcinogenesis.
- Gene therapy is being explored as a novel treatment strategy for prostate cancer.
Purpose of the Study:
- To review gene therapy approaches for prostate cancer.
- To discuss gene delivery systems for therapeutic gene transfer.
- To highlight potential gene targets and technologies for prostate cancer treatment.
Main Methods:
- Evaluation of gene delivery systems: retroviral, adenoviral, and liposomal vectors.
- Consideration of ex vivo, in vivo, and cell culture study designs.
- Exploration of gene transfer and expression strategies targeting key genes in prostate carcinogenesis.
Main Results:
- Gene therapy approaches are under investigation for human prostate cancer.
- Delivery systems present both advantages and drawbacks for clinical application.
- Targeting tumor suppressor p53 and other implicated genes shows therapeutic promise.
Conclusions:
- Gene therapy, particularly using tumor suppressor genes like p53, holds therapeutic potential for prostate cancer.
- Utilizing prostate-specific elements for gene expression and targeting key genes (androgen receptor, insulin-like growth factor) may be effective.
- Further research into gene transfer and delivery systems is crucial for advancing prostate cancer treatment.